Cadila receives tentative FDA approval for Gatifloxacin tablets

By Angela McDaniels

Seattle, Nov. 29 - Cadila Healthcare Ltd. said it has received tentative approval from the U.S. Food and Drug Administration to market Gatifloxacin 200 mg and 400 mg tablets in the United States.

U.S. sales of Gatifloxacin are estimated at $200 million, the company said.

Cadila will market the broad spectrum anti-bacterial agent through its U.S. subsidiary Zydus Pharmaceuticals Inc. following patent expiry.

Cadila Healthcare is a pharmaceutical company based in Ahmedabad, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.